Citius Oncology (CTOR) Stock Chart & Stock Price History $1.66 +0.05 (+2.80%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Citius Oncology Stock Price Performance The Citius Oncology (CTOR) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 14.25%, with a year-to-date return of 43.91%. In the past month, the stock has increased 11.82%, reflecting recent market activity. As of the latest close, Citius Oncology traded at $1.61 with a market cap of $126.18 million and volume of 109,927 shares. Receive CTOR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-2.07%1 Month Performance+11.82%3 Month Performance+89.03%Year-To-Date Performance+43.91%1 Year Performance-14.25% CTOR Stock Chart for Thursday, August, 21, 2025 CTOR Chart by TradingView Citius Oncology Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/20/2025$1.70$1.61-5.29%$1.74$1.61109,927 shs$126.18 million08/19/2025$1.75$1.70-2.86%$1.82$1.58163,238 shs$133.23 million08/18/2025$1.69$1.75+3.55%$1.81$1.69100,206 shs$137.15 million08/15/2025$1.72$1.69-1.74%$1.76$1.6659,776 shs$132.45 million08/14/2025$1.79$1.72-3.91%$1.87$1.62277,236 shs$134.80 million08/13/2025$1.69$1.79+5.92%$1.80$1.70168,659 shs$140.28 million08/12/2025$1.72$1.69-1.74%$1.77$1.67133,639 shs$132.45 million08/11/2025$1.81$1.72-4.97%$1.85$1.71174,158 shs$134.80 million08/08/2025$1.85$1.81-2.16%$1.94$1.74158,296 shs$141.85 million08/07/2025$1.91$1.85-3.14%$1.99$1.75230,639 shs$149.69 million Get the Latest News and Ratings for CTOR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. 08/06/2025$1.81$1.91+5.52%$2.04$1.88271,065 shs$149.69 million08/05/2025$2.06$1.81-12.14%$2.06$1.81365,870 shs$141.85 million08/04/2025$2.06$2.06$2.12$2.05192,774 shs$161.44 million08/01/2025$2.21$2.06-6.79%$2.31$2.06608,706 shs$161.44 million07/31/2025$2.16$2.21+2.31%$2.33$2.19382,703 shs$173.20 million07/30/2025$2.06$2.16+4.85%$2.37$2.061.34 million shs$169.28 million07/29/2025$1.87$2.06+10.16%$2.30$1.821.62 million shs$161.44 million07/28/2025$1.97$1.87-5.08%$2.00$1.75565,431 shs$146.55 million07/25/2025$1.95$1.97+1.03%$2.38$1.952.28 million shs$154.39 million07/24/2025$1.82$1.95+7.14%$1.99$1.811.13 million shs$152.82 million07/23/2025$1.65$1.82+10.30%$2.84$1.7019.53 million shs$142.64 million07/22/2025$1.48$1.65+11.49%$1.70$1.47432,580 shs$118.06 million07/21/2025$1.53$1.48-3.27%$1.59$1.47342,255 shs$105.89 million Related Companies Palvella Therapeutics Stock Chart Sage Therapeutics Stock Chart SNDL Stock Chart Arvinas Stock Chart Opthea Stock Chart Savara Stock Chart Bicycle Therapeutics Stock Chart Septerna Stock Chart Zevra Therapeutics Stock Chart Autolus Therapeutics Stock Chart Receive CTOR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CTOR) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access